Drugs / MTP 101-LF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05333471 | Aug 2022 → Mar 2027 expected | chronic granulomatous disease | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTP-101-LF | “Each unit of MTP-101-LF contains approximately 35 mL of fecal transplant product.” NCT05333471 ↗ |
| Route | Other | “Participants will receive approximately 32 mL via colonoscopy.” NCT05333471 ↗ |